# World Journal of *Clinical Cases*

World J Clin Cases 2022 October 6; 10(28): 9970-10390





Published by Baishideng Publishing Group Inc

W J C C World Journal of Clinical Cases

#### Contents

#### Thrice Monthly Volume 10 Number 28 October 6, 2022

#### **REVIEW**

9970 COVID-19 and the heart

> Xanthopoulos A, Bourazana A, Giamouzis G, Skoularigki E, Dimos A, Zagouras A, Papamichalis M, Leventis I, Magouliotis DE, Triposkiadis F, Skoularigis J

9985 Role of short chain fatty acids in gut health and possible therapeutic approaches in inflammatory bowel diseases

Caetano MAF, Castelucci P

#### **MINIREVIEWS**

10004 Review of the pharmacological effects of astragaloside IV and its autophagic mechanism in association with inflammation

Yang Y, Hong M, Lian WW, Chen Z

#### **ORIGINAL ARTICLE**

#### **Clinical and Translational Research**

Effects of targeted-edited oncogenic insulin-like growth factor-1 receptor with specific-sgRNA on 10017 biological behaviors of HepG2 cells

Yao M, Cai Y, Wu ZJ, Zhou P, Sai WL, Wang DF, Wang L, Yao DF

#### **Retrospective Study**

10031 Analysis of the successful clinical treatment of 140 patients with parathyroid adenoma: A retrospective study

Peng ZX, Qin Y, Bai J, Yin JS, Wei BJ

10042 Efficacy of digital breast tomosynthesis combined with magnetic resonance imaging in the diagnosis of early breast cancer

Ren Y, Zhang J, Zhang JD, Xu JZ

Prevention and management of adverse events following COVID-19 vaccination using traditional Korean 10053 medicine: An online survey of public health doctors

Kang B, Chu H, Youn BY, Leem J

- 10066 Clinical outcomes of targeted therapies in elderly patients aged  $\geq 80$  years with metastatic colorectal cancer Jang HR, Lee HY, Song SY, Lim KH
- 10077 Endovascular treatment vs drug therapy alone in patients with mild ischemic stroke and large infarct cores Kou WH, Wang XQ, Yang JS, Qiao N, Nie XH, Yu AM, Song AX, Xue Q



#### Contents

#### Thrice Monthly Volume 10 Number 28 October 6, 2022

#### **Clinical Trials Study**

10085 One hundred and ninety-two weeks treatment of entecavir maleate for Chinese chronic hepatitis B predominantly genotyped B or C

Xu JH, Wang S, Zhang DZ, Yu YY, Si CW, Zeng Z, Xu ZN, Li J, Mao Q, Tang H, Sheng JF, Chen XY, Ning Q, Shi GF, Xie Q, Zhang XQ, Dai J

#### **Observational Study**

10097 Dementia-related contact experience, attitudes, and the level of knowledge in medical vocational college students

Liu DM, Yan L, Wang L, Lin HH, Jiang XY

#### SYSTEMATIC REVIEWS

10109 Link between COVID-19 vaccines and myocardial infarction

Zafar U, Zafar H, Ahmed MS, Khattak M

#### **CASE REPORT**

10120 Successful treatment of disseminated nocardiosis diagnosed by metagenomic next-generation sequencing: A case report and review of literature

Li T, Chen YX, Lin JJ, Lin WX, Zhang WZ, Dong HM, Cai SX, Meng Y

10130 Multiple primary malignancies - hepatocellular carcinoma combined with splenic lymphoma: A case report

Wu FZ, Chen XX, Chen WY, Wu OH, Mao JT, Zhao ZW

- 10136 Metastatic multifocal melanoma of multiple organ systems: A case report Maksimaityte V, Reivytyte R, Milaknyte G, Mickys U, Razanskiene G, Stundys D, Kazenaite E, Valantinas J, Stundiene I
- 10146 Cavernous hemangioma of the ileum in a young man: A case report and review of literature Yao L, Li LW, Yu B, Meng XD, Liu SQ, Xie LH, Wei RF, Liang J, Ruan HQ, Zou J, Huang JA
- 10155 Successful management of a breastfeeding mother with severe eczema of the nipple beginning from puberty: A case report

Li R, Zhang LX, Tian C, Ma LK, Li Y

10162 Short benign ileocolonic anastomotic strictures - management with bi-flanged metal stents: Six case reports and review of literature

Kasapidis P, Mavrogenis G, Mandrekas D, Bazerbachi F

- 10172 Simultaneous bilateral floating knee: A case report Wu CM, Liao HE, Lan SJ
- 10180 Chemotherapy, transarterial chemoembolization, and nephrectomy combined treated one giant renal cell carcinoma (T3aN1M1) associated with Xp11.2/TFE3: A case report Wang P, Zhang X, Shao SH, Wu F, Du FZ, Zhang JF, Zuo ZW, Jiang R

10186 Tislelizumab-related enteritis successfully treated with adalimumab: A case report Chen N, Qian MJ, Zhang RH, Gao QQ, He CC, Yao YK, Zhou JY, Zhou H



<b>C t</b>	World Journal of Clinical Cases
Conten	Thrice Monthly Volume 10 Number 28 October 6, 2022
10193	Treatment of refractory/relapsed extranodal NK/T cell lymphoma with decitabine plus anti-PD-1: A case report
	Li LJ, Zhang JY
10201	Clinical analysis of pipeline dredging agent poisoning: A case report
	Li YQ, Yu GC, Shi LK, Zhao LW, Wen ZX, Kan BT, Jian XD
10208	Follicular lymphoma with cardiac involvement in a 90-year-old patient: A case report Sun YX, Wang J, Zhu JH, Yuan W, Wu L
10214	Twin reversed arterial perfusion sequence-a rare and dangerous complication form of monochorionic twins: A case report
	Anh ND, Thu Ha NT, Sim NT, Toan NK, Thuong PTH, Duc NM
10220	Potential otogenic complications caused by cholesteatoma of the contralateral ear in patients with otogenic abscess secondary to middle ear cholesteatoma of one ear: A case report
	Zhang L, Niu X, Zhang K, He T, Sun Y
10227	Myeloid sarcoma with ulnar nerve entrapment: A case report
	Li DP, Liu CZ, Jeremy M, Li X, Wang JC, Nath Varma S, Gai TT, Tian WQ, Zou Q, Wei YM, Wang HY, Long CJ, Zhou Y
10236	Alpha-fetoprotein-producing hepatoid adenocarcinoma of the lung responsive to sorafenib after multiline treatment: A case report
	Xu SZ, Zhang XC, Jiang Q, Chen M, He MY, Shen P
10244	Acute mesenteric ischemia due to percutaneous coronary intervention: A case report
	Ding P, Zhou Y, Long KL, Zhang S, Gao PY
10252	Persistent diarrhea with petechial rash - unusual pattern of light chain amyloidosis deposition on skin and gastrointestinal biopsies: A case report
	Bilton SE, Shah N, Dougherty D, Simpson S, Holliday A, Sahebjam F, Grider DJ
10260	Solitary splenic tuberculosis: A case report
	Guo HW, Liu XQ, Cheng YL
10266	Coronary artery aneurysms caused by Kawasaki disease in an adult: A case report and literature review
	He Y, Ji H, Xie JC, Zhou L
10273	Double filtration plasmapheresis for pregnancy with hyperlipidemia in glycogen storage disease type Ia: A case report
	Wang J, Zhao Y, Chang P, Liu B, Yao R
10279	Treatment of primary tracheal schwannoma with endoscopic resection: A case report
	Shen YS, Tian XD, Pan Y, Li H
10286	Concrescence of maxillary second molar and impacted third molar: A case report
	Su J, Shao LM, Wang LC, He LJ, Pu YL, Li YB, Zhang WY



World Journal of Clinical Cases				
Conten	Thrice Monthly Volume 10 Number 28 October 6, 2022			
10293	Rare leptin in non-alcoholic fatty liver cirrhosis: A case report			
	Nong YB, Huang HN, Huang JJ, Du YQ, Song WX, Mao DW, Zhong YX, Zhu RH, Xiao XY, Zhong RX			
10301	One-stage resection of four genotypes of bilateral multiple primary lung adenocarcinoma: A case report <i>Zhang DY, Liu J, Zhang Y, Ye JY, Hu S, Zhang WX, Yu DL, Wei YP</i>			
10310	Ectopic pregnancy and failed oocyte retrieval during <i>in vitro</i> fertilization stimulation: Two case reports <i>Zhou WJ, Xu BF, Niu ZH</i>			
10317	Malignant peritoneal mesothelioma with massive ascites as the first symptom: A case report <i>Huang X, Hong Y, Xie SY, Liao HL, Huang HM, Liu JH, Long WJ</i>			
10326	Subperiosteal orbital hematoma concomitant with abscess in a patient with sinusitis: A case report <i>Hu XH, Zhang C, Dong YK, Cong TC</i>			
10332	Postpartum posterior reversible encephalopathy syndrome secondary to preeclampsia and cerebrospinal fluid leakage: A case report and literature review			
	Wang Y, Zhang Q			
10339	Sudden extramedullary and extranodal Philadelphia-positive anaplastic large-cell lymphoma transformation during imatinib treatment for CML: A case report			
	Wu Q, Kang Y, Xu J, Ye WC, Li ZJ, He WF, Song Y, Wang QM, Tang AP, Zhou T			
10346	Relationship of familial cytochrome P450 4V2 gene mutation with liver cirrhosis: A case report and review of the literature			
	Jiang JL, Qian JF, Xiao DH, Liu X, Zhu F, Wang J, Xing ZX, Xu DL, Xue Y, He YH			
10358	COVID-19-associated disseminated mucormycosis: An autopsy case report			
	Kyuno D, Kubo T, Tsujiwaki M, Sugita S, Hosaka M, Ito H, Harada K, Takasawa A, Kubota Y, Takasawa K, Ono Y, Magara K, Narimatsu E, Hasegawa T, Osanai M			
10366	Thalidomide combined with endoscopy in the treatment of Cronkhite-Canada syndrome: A case report			
	Rong JM, Shi ML, Niu JK, Luo J, Miao YL			
10375	Thoracolumbar surgery for degenerative spine diseases complicated with tethered cord syndrome: A case report			
	Wang YT, Mu GZ, Sun HL			
	LETTER TO THE EDITOR			
10384	Are pregnancy-associated hypertensive disorders so sweet?			

Thomopoulos C, Ilias I

10387 Tumor invasion front in oral squamous cell carcinoma Cuevas-González JC, Cuevas-González MV, Espinosa-Cristobal LF, Donohue Cornejo A

#### Contents

Thrice Monthly Volume 10 Number 28 October 6, 2022

#### **ABOUT COVER**

Editorial Board Member of World Journal of Clinical Cases, Kaleem Ullah, FCPS, MBBS, Assistant Professor, Solid Organ Transplantation and Hepatobiliary Surgery, Pir Abdul Qadir Shah Jeelani Institute of Medical Sciences, Gambat 66070, Sindh, Pakistan. drkaleempk@gmail.com

#### **AIMS AND SCOPE**

The primary aim of World Journal of Clinical Cases (WJCC, World J Clin Cases) is to provide scholars and readers from various fields of clinical medicine with a platform to publish high-quality clinical research articles and communicate their research findings online.

WJCC mainly publishes articles reporting research results and findings obtained in the field of clinical medicine and covering a wide range of topics, including case control studies, retrospective cohort studies, retrospective studies, clinical trials studies, observational studies, prospective studies, randomized controlled trials, randomized clinical trials, systematic reviews, meta-analysis, and case reports.

#### **INDEXING/ABSTRACTING**

The WJCC is now abstracted and indexed in Science Citation Index Expanded (SCIE, also known as SciSearch®), Journal Citation Reports/Science Edition, Current Contents®/Clinical Medicine, PubMed, PubMed Central, Scopus, Reference Citation Analysis, China National Knowledge Infrastructure, China Science and Technology Journal Database, and Superstar Journals Database. The 2022 Edition of Journal Citation Reports® cites the 2021 impact factor (IF) for WJCC as 1.534; IF without journal self cites: 1.491; 5-year IF: 1.599; Journal Citation Indicator: 0.28; Ranking: 135 among 172 journals in medicine, general and internal; and Quartile category: Q4. The WJCC's CiteScore for 2021 is 1.2 and Scopus CiteScore rank 2021: General Medicine is 443/826.

#### **RESPONSIBLE EDITORS FOR THIS ISSUE**

Production Editor: Xu Guo; Production Department Director: Xiang Li; Editorial Office Director: Jin-Lei Wang.

NAME OF JOURNAL	INSTRUCTIONS TO AUTHORS
World Journal of Clinical Cases	https://www.wignet.com/bpg/gerinfo/204
<b>ISSN</b>	GUIDELINES FOR ETHICS DOCUMENTS
ISSN 2307-8960 (online)	https://www.wjgnet.com/bpg/GerInfo/287
LAUNCH DATE	GUIDELINES FOR NON-NATIVE SPEAKERS OF ENGLISH
April 16, 2013	https://www.wignet.com/bpg/gerinfo/240
FREQUENCY	PUBLICATION ETHICS
Thrice Monthly	https://www.wjgnet.com/bpg/GerInfo/288
<b>EDITORS-IN-CHIEF</b> Bao-Gan Peng, Jerzy Tadeusz Chudek, George Kontogeorgos, Maurizio Serati, Ja Hyeon Ku	PUBLICATION MISCONDUCT https://www.wjgnet.com/bpg/gerinfo/208
EDITORIAL BOARD MEMBERS	ARTICLE PROCESSING CHARGE
https://www.wjgnet.com/2307-8960/editorialboard.htm	https://www.wjgnet.com/bpg/gerinfo/242
PUBLICATION DATE	STEPS FOR SUBMITTING MANUSCRIPTS
October 6, 2022	https://www.wignet.com/bpg/GerInfo/239
COPYRIGHT	ONLINE SUBMISSION
© 2022 Baishideng Publishing Group Inc	https://www.f6publishing.com

© 2022 Baishideng Publishing Group Inc. All rights reserved. 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA E-mail: bpgoffice@wjgnet.com https://www.wjgnet.com



W J C C World Journal of Clinical Cases

Submit a Manuscript: https://www.f6publishing.com

World J Clin Cases 2022 October 6; 10(28): 10109-10119

DOI: 10.12998/wjcc.v10.i28.10109

ISSN 2307-8960 (online)

SYSTEMATIC REVIEWS

# Link between COVID-19 vaccines and myocardial infarction

Umema Zafar, Hamna Zafar, Mian Saad Ahmed, Madiha Khattak

Specialty type: Cardiac and cardiovascular systems

Provenance and peer review: Invited article; Externally peer reviewed.

Peer-review model: Single blind

### Peer-review report's scientific quality classification

Grade A (Excellent): 0 Grade B (Very good): B, B Grade C (Good): C, C Grade D (Fair): 0 Grade E (Poor): 0

P-Reviewer: Kirkik D, Turkey; Krishnamoorthy Y, India; Munteanu C, Romania

Received: May 30, 2022 Peer-review started: May 30, 2022 First decision: July 14, 2022 Revised: July 20, 2022 Accepted: September 1, 2022 Article in press: September 1, 2022 Published online: October 6, 2022



Umema Zafar, Madiha Khattak, Department of Physiology, Khyber Medical College, Peshawar 25000, Pakistan

Hamna Zafar, Department of Medicine, Khyber Teaching Hospital, Peshawar 25000, Pakistan

Mian Saad Ahmed, Department of Forensic Medicine, Khyber Medical College, Peshawar 25000, Pakistan

Corresponding author: Umema Zafar, MBBS, MPhil, Assistant Professor, Doctor, Department of Physiology, Khyber Medical College, Peshawar University Campus, Peshawar 25000, Pakistan. umema.com@gmail.com

## Abstract

#### BACKGROUND

Vaccines for coronavirus disease 2019 (COVID-19) include ChAdOx1-SARS-COV-2 (AstraZeneca), Ad26.COV2.S (Janssen), mRNA-1273 (Moderna), BNT162b2 (Pfizer), BBIBP-CorV (Sinopharm), CoronaVac (Sinovac), and Bharat Biotech BBV152 (Covaxin).

#### AIM

To find the association between COVID-19 vaccines and myocardial infarction (MI).

### **METHODS**

This is a systematic review that involved searching databases such as MEDLINE, EMBASE, and PakMediNet after making a search strategy using MeSH and Emtree terms. Eligibility criteria were set, and studies having no mention of MI as a complication of COVID-19 vaccination, protocols, genetic studies, and animal studies were excluded. Data was extracted using a predesigned extraction table, and 29 studies were selected after screening and applying the eligibility criteria.

#### RESULTS

The majority of studies mentioned AstraZeneca (18 studies) followed by Pfizer (14 studies) and Moderna (9 studies) in subjects reporting MI after vaccination. Out of all the studies, 69% reported MI cases after the first COVID-19 vaccination dose and 14% after the second, 44% reported ST-segment elevation MI, and 26% reported non-ST-segment elevation MI. The mortality rate was 29% after MI.

#### CONCLUSION

In conclusion, many studies linked MI to COVID-19 vaccinations, but no definitive association could be found.



**Key Words:** SARS-CoV-2 infection; Vaccination; Myocardial infarction; Association; Pfizer; AstraZeneca; Moderna; Sinovac; Janssen; Covaxin

©The Author(s) 2022. Published by Baishideng Publishing Group Inc. All rights reserved.

**Core Tip:** Mechanisms like vaccine-induced thrombotic thrombocytopenia and myocarditis complication have been identified in the literature linking myocardial infarction with coronavirus disease 2019 (COVID-19) vaccination. The majority of myocardial infarction cases reported were after vaccination with the vaccine from AstraZeneca, were ST-segment elevation, and were reported after first dose of vaccine. Although there are reports of myocardial infarction after COVID-19 vaccination, no definitive link was found in the previous literature linking the two.

Citation: Zafar U, Zafar H, Ahmed MS, Khattak M. Link between COVID-19 vaccines and myocardial infarction. World J Clin Cases 2022; 10(28): 10109-10119 URL: https://www.wjgnet.com/2307-8960/full/v10/i28/10109.htm DOI: https://dx.doi.org/10.12998/wjcc.v10.i28.10109

#### INTRODUCTION

Coronavirus disease 2019 (COVID-19) is an infectious disease caused by severe acute respiratory syndrome coronavirus 2. The first case of COVID-19 was reported in Wuhan, China and rapidly spread to the rest of the world[1]. The COVID-19 outbreak was declared a pandemic on March 11, 2020[2]. Although severe acute respiratory syndrome coronavirus 2 primarily affects the respiratory tract, it frequently causes cardiac, gastrointestinal, hepatic, nephrological, and central nervous system distress [3]. It mainly causes nonspecific symptoms like fever, cough, and myalgia; however, in severe cases, it can lead to respiratory failure, septic shock, multiorgan dysfunction, and even death[4].

COVID-19 treatment is most often general supportive care and nutritional support in addition to respiratory care. However, due to the lack of clinically approved interventions for COVID-19 treatment, attempts have been made for vaccine development to prevent the disease[3]. As a result, the safety and efficacy of several vaccines have been approved by the World Health Organization. Among these are AstraZeneca/Oxford, Johnson and Johnson/Janssen, Moderna, Pfizer/BioNTech, Sinopharm, Sinovac, and the Bharat Biotech BBV152 Covaxin vaccine[5]. Vaccines for severe acute respiratory syndrome coronavirus 2 have several different mechanisms of action, including: (1) RNA and DNA vaccines that are genetically engineered to produce a protein that warrants an immune response; (2) Vector vaccines that introduce a type of virus that cannot produce disease but can effectively generate an immune response; (3) Vaccines that use genetically modified viruses to become weaker or inactivated in order not to cause virulence but retain their antigenicity; and (4) Harmless fragments of proteins or protein shells with similar antigenicity to the COVID-19 virus that are used in protein-based vaccines to produce immunity[5].

It is not uncommon to experience side effects following a COVID-19 vaccine. Fatigue, headache, muscle pain, joint pain, chills, fever, generalized body pain, and local reaction at the injection site are some of the side effects that have been reported after COVID-19 vaccination[6]. Several cardiovascular adverse effects have also been reported after COVID-19 vaccination, including myocarditis, pericarditis, and thrombotic events. Additionally, rare cardiovascular events such as hypertension, acute coronary syndrome, stress cardiomyopathy, arrhythmias, and cardiac arrest have also been reported. Although the relationship between these rare events and the vaccination is doubtful, the incidence of these rare side effects post vaccination in the absence of any other obvious cause in otherwise healthy individuals may suggest a causal relationship between the two[7].

When only focusing on myocardial infarction (MI), it is observed that after a person experiences an MI, there is a 20% chance of mortality in the 1<sup>st</sup> year and 10% thereafter[8]. According to Johansson *et al* [9], the relative risk of cardiovascular morbidity and mortality was 30% higher in those who suffered from MI compared to the general population. The aims of this review were to identify the pathophysiological links between MI and COVID-19 vaccination and investigate the doses and frequencies of COVID-19 vaccines, the types of MI, and mortality statistics linked with the vaccine administration in the available literature.

Zaishideng® WJCC | https://www.wjgnet.com

Table 1 Concept table for building the search strategy								
	Concept 1	Concept 2	Concept 3	Concept 4				
Key concepts	COVID-19	Vaccines	Myocardial infarction	Link				
Free text terms		Vaccination	Heart attack	Relation				
		Shot		Interrelation				
		Jab						
		Dose						
		Booster						
Booster Controlled vocabulary terms (MeSH terms, Emtree 2019 novel coronavirus Viral Vaccines Anterior wall myocardial infarctior terms)		Association						
ternis)	2019-nCoV disease	Immunization						
	2019-nCoV infection	Concept 2 Concept 3 Concept 3   Vaccines Myocardial infarction Link   Vaccination Heart attack Relation   Vaccination Heart attack Relation   Shot Internation Internation   Jab Dose Booster   coronavirus Viral Vaccines Anterior wall myocardial infarction   disease Immunization Inferior wall myocardial infarction   pandemic Non-ST elevated myocardial infarction   virus disease ST elevation myocardial infarction						
	COVID-19 pandemic		Non-ST elevated myocardial					
	COVID-19 virus disease		ST algoration myocardial information					
	COVID-19 virus infection		Si elevatori myocardiar marcuon					
	SARS-CoV-2 infection							

SARS-CoV-2: Severe acute respiratory syndrome coronavirus 2; COVID-19: Coronavirus disease 2019.

#### MATERIALS AND METHODS

#### Databases and search strategy

This systematic review was conducted over a period of 6 mo. The databases searched were MEDLINE, EMBASE, and PakMediNet. MeSH and Emtree terms were used as well as free text words (Table 1) to develop a search strategy. Various concepts were identified and then searched using Boolean operators. "AND" was used to separate various concepts, and synonyms for a single concept were separated by "OR." The data was searched, and studies from the first delivery of COVID-19 vaccines in December 2020 until May 1, 2022 were included.

#### Eligibility criteria

Articles that mentioned COVID-19 vaccination along with MI as a vaccine complication were included. Case reports, case series, original research, and systematic reviews were also included.

#### Exclusion criteria

All studies that included COVID-19 cases but had no mention of vaccinations were excluded. Studies with no mention of MI as a complication of a COVID-19 vaccination were also excluded. Protocols and research based on animals and studies mentioning vaccinations for similar diseases, like influenza, were also excluded. Genetic studies involving COVID-19 without mention of vaccination and narrative reviews not identifying a link between MI and COVID-19 vaccination were further excluded (Figure 1).

#### Data extraction

The data was then extracted from the eligible studies by a structured data extraction form. Two independent researchers were engaged in both screening and data extraction, and data was analyzed for frequencies and percentages.

#### RESULTS

A total of 56 studies were identified, but only 29 were selected after applying the eligibility criteria (Table 2)[5-7,10-35]. The majority of these were case reports that reported the incidence of MI after COVID-19 vaccination but could not prove any causative relationship between the two. They also could not prove whether MI was due to vaccination-related changes in the body. The majority of side effects reported were from AstraZeneca followed by Pfizer and Moderna vaccines (Figure 2).

Based on the studies included in this report, patients usually suffered from MI after the first dose of the vaccine (69%). Of these studies, 53.3% of case reports reported MI within a few hours of vaccine



#### Table 2 Analysis/summary of important findings in various studies

Ref.	Study design	No. of cases reported	Type of vaccine given	Time during symptoms and vaccination	Dose of vaccine, 1 <sup>st</sup> or 2 <sup>nd</sup>	Type of MI	Patient outcome, dead or alive
Jabagi <i>et al</i> [ <mark>10</mark> ]	Cross sectional	6510/11113 (58.6%) after first dose, 4843/11113 (43.6%) after second dose of vaccine	Pfizer	Not given	1 <sup>st</sup> and 2 <sup>nd</sup> both	Not given	NA
Li et al[ <mark>11</mark> ]	Cohort study	Ages 35-74 incidence = between 1/100 and 1/1000 ages 75 and above incidence = between 1/10 and 1/100 patients	NA	Not given	NA	Not given	NA
Aye et al[12]	Cohort and systematic review	29 in cohort, 35 in systematic review	Pfizer 30/35 (86%), Moderna 1/35 (3%), AstraZeneca 4/35 (11%), Janssen 0%	Median of 1 d	2 <sup>nd</sup>	STEMI 20/35 (57%) NSTEMI 15/35 (43%)	1 dead, remaining were alive
Maadarani <i>et al</i> [ <mark>13</mark> ]	Case report	1	AstraZeneca	1.5 h	1 <sup>st</sup>	STEMI and NSTEMI	Alive
Fazlollahi <i>et al</i> [ <mark>14</mark> ]	Systematic review	3	2 Pfizer, 1 Moderna	Case 1: 6 h, case 2: 1 h, case 3: 30 min	1 <sup>st</sup>	Case 1: NSTEMI, case 2: STEMI, case 3: STEMI	Case 1: alive, case 2: alive, case 3: dead
Şancı et al[15]	Case report	1	Pfizer	15 min	1 <sup>st</sup>	STEMI	Alive
Chatterjee <i>et al</i> [16]	Case report	1	AstraZeneca	2 d	1 <sup>st</sup>	STEMI	Alive
Jeet Kaur <i>et al</i> [ <mark>17</mark> ]	Cross sectional	Pfizer: 44, AstraZeneca: 1, Moderna: 3	Pfizer, AstraZeneca, and Moderna	NA	NA	NA	NA
Iqbal et al[18]	Case report	1	Moderna	90 min	1 <sup>st</sup>	NSTEMI	Alive
Cari <i>et al</i> [ <mark>19</mark> ]	Cross sectional	Pfizer: 0.00044%, AstraZeneca: 0.00168%, Janssen: 0.00217%	Pfizer, AstraZeneca, Janssen	Not given	NA	NA	Dead Pfizer: 0.00013%, AstraZeneca: 0.0004%, Janssen: 0.00048%
Tajstra <i>et al</i> [20]	Case report	1	Pfizer	30 min	1 <sup>st</sup>	STEMI	Dead
Flower <i>et al</i> [21]	Case report	1	AstraZeneca	8 d	1 <sup>st</sup>	STEMI	Alive
Chiang <i>et al</i> [22]	Case report	1	AstraZeneca	8 d	1 <sup>st</sup>	NSTEMI	Alive
Fialho <i>et al</i> [23]	Case report	1	AstraZeneca	20 min	1 <sup>st</sup>	STEMI	Alive
Hsu et al[24]	Case report	1	AstraZeneca	9 d	1 <sup>st</sup>	STEMI	Dead
Showkathali <i>et</i> al[25]	Cross sectional	37 (42%)	AstraZeneca was the most used vaccine-28 (76%), while 9 (24%) had Covaxin	<1 wk: 9 (24%), 1-4 wk: 19 (52%), and >4 wk: 9 (24%)	1 <sup>st</sup> (65%), 2 <sup>nd</sup> dose (35%)	STEMI and NSTEMI	NA
Whiteley et al	Cross sectional	Post vaccination < 28 d 3814/13787 (27.66%). Post	AstraZeneca and Pfizer	NA	1 <sup>st</sup>	NA	Dead, < 28 d 16192/43766

[26]		vaccination > 28 d 2050/7758 (26.42%)					(37.00%), > 28 d 11738/19496 (60.21%)
Shiravi <i>et al</i> [ <mark>5</mark> ]	Narrative review	Not given	Pfizer, AstraZeneca, and Sinovac vaccines	15 min to 2 d	NA	NA	NA
Barda et al[ <mark>27</mark> ]	Cross sectional	59/892785 = 0.006%	Pfizer	Not given	NA	NA	NA
Barsha et al <mark>[6</mark> ]	Case report	1	Moderna	12 h	1 <sup>st</sup>	NSTEMI	Alive
Boivin <i>et al</i> [28]	Case report	1	Moderna	1 h	1 <sup>st</sup>	STEMI	Alive
Hippisley-Cox et al[29]	Cross sectional	AstraZeneca: 0-7 d 1983/22079 (8.98%), 8-21 d 4028/22079 (18.23%), 22-28 d 1889/22.79 (8.55%). Pfizer: 0-7 d 1578/15124 (10.43%), 8-21 d 3457/15124 (22.83%), 22-28 d 1510/15124 (10.00%)	AstraZeneca and Pfizer	AstraZeneca: 0-7 d 1983, 8-21 d 4028, 22-28 d 1889, Pfizer: 0-7 d 1578, 8-21 d 3457, 22-28 d 1510	1 <sup>st</sup>	Not given	Not given
Edler <i>et al</i> [30]	Case series	1	Pfizer	2 d	1 <sup>st</sup>	Not given	Dead
Hana et al[7]	Systematic review	1644 cases total	AstraZeneca, Pfizer and Moderna	NA	NA	Not given	NA
Ho et al <mark>[31</mark> ]	Systematic review	10	Pfizer, Moderna, AstraZeneca, Sinovac	NA	1 <sup>st</sup>	STEMI and NSTEMI	Some dead, some alive
Sung et al[32]	Case series	2	Moderna	Case 1 < 24 h, case 2 < 12 h	1 <sup>st</sup>	Case 1 STEMI, case 2 Not given	Alive
Pottegård <i>et al</i> [ <mark>33</mark> ]	Cross sectional	Incidence rate 1.04/1.21, no of cases 20	AstraZeneca	Not given	1 <sup>st</sup>	Not given	NA
Agostino <i>et al</i> [ <mark>34</mark> ]	Case report	1	AstraZeneca	12 d	1 <sup>st</sup>	Not given	Dead
Bardenheier <i>et</i> al[35]	Cross sectional	1	Pfizer	2 d	2 <sup>nd</sup>	Not given	NA

MI: Myocardial infarction; NA: Not available; STEMI: ST-segment elevation myocardial infarction; NSTEMI: Non-ST-segment elevation myocardial infarction; NA: Not Applicable.

administration and the rest within 10 d. Out of these patients, 44% of cases reported were of ST-segment elevation MI (STEMI), and 26% were non-ST-segment elevation MI (NSTEMI). The mortality rate was 29% (Figure 3). The most studies reported were from the United States, the United Kingdom, and India (Figure 4).

Possible mechanisms behind MI that have been identified after the literature review are as follows: (1) Kounis syndrome, which can cause MI through different mechanisms like allergic vasospasm and stent occlusion with a thrombus infiltrated by eosinophils or mast cells; (2) Vaccine-induced thrombotic thrombocytopenia; (3) Acute coronary syndrome after influenza vaccine administration as both influenza and COVID-19 vaccines share a common excipient (polysorbate 80); (4) Demand-supply mismatch ischemia, which can be caused by the stress of getting the vaccine in elderly people with other associated comorbidities; and (5) Myocarditis.



DOI: 10.12998/wjcc.v10.i28.10109 Copyright ©The Author(s) 2022.

Figure 1 PRISMA flow chart showing the selection process. ACE2: Angiotensin-converting enzyme 2; SARS-CoV-2: Severe acute respiratory syndrome coronavirus 2; COVID-19: Coronavirus disease 2019.

#### DISCUSSION

Globally, 65.8% of people have received at least one dose of a COVID-19 vaccine, and 11.79 billion doses have been administered globally [36]. The doses of various vaccines administered through May 25, 2022 are as follows: Pfizer, 613 million; Moderna, 147 million; AstraZeneca, 67 million; Janssen, 19 million; Sputnik V, 1.85 million; Sinopharm, 2.31 million; Sinovac, 3737; and Covaxin, 44. Pakistan has administered at least 248672457 doses of COVID-19 vaccines so far. Assuming that every person needs two doses, that is enough to have vaccinated about 57.4% of the country's population[37].

MI remains one of the rare complications of a COVID-19 vaccination[7]. In this review, nearly 69% of the studies reported MI occurrence after the first dose, and 14% reported it after the second. It is a known fact that a subsequent or a booster dose of a vaccine is given to increase the antibody titer. This is especially crucial in those with a weakened immune response due to comorbidities[38]. A theory based on this finding is that since MI occurrence is higher after the first vaccine dose, immune response probably plays no role or only a minimal role in MI pathophysiology. If MI was due to overstimulation of the immune system, then the frequency of MI after the second dose would be higher.

A study showed that COVID-19 vaccination produces an optimum immune response in chronic inflammatory disease patients on immunosuppressive therapy, and the risk of adverse consequences is not higher than in the normal population [39]. No single inflammatory biomarker of systemic manifestations of vaccines has been identified but rather a battery of biomarkers, specifically, interleukin-6, Creactive protein, and the interferon signaling pathway. A vaccine starts its action within minutes, starting from the injection site and spreading throughout the body. The factors known to affect the reactogenicity of various COVID-19 vaccines are age, gender, psychological/physical stressors, obesity, pre-existing immunity, vaccine characteristics (route, site, and method of vaccine administration), vaccine composition, antigen type, combination, and dose[40].

According to McManus et al[41], the incidence of STEMI compared to NSTEMI has reduced over the past few years. In the present research, patients with STEMI were present in 44% of the studies compared to 26% with NSTEMI after COVID-19 vaccination[41]. A recent case reported STEMI in a





Figure 2 Frequency of vaccines given to subjects in each study.



DOI: 10.12998/wjcc.v10.i28.10109 Copyright ©The Author(s) 2022.

Figure 3 Characteristics of research studies analyzed. A: Doses of vaccines given to subjects/participants in studies analyzed; B: Percentage/frequencies of types of myocardial infarction reported in studies analyzed; C: Type of studies analyzed; D: Mortality status of subjects/participants in various studies after suffering from myocardial infarction post-vaccination. MI: Myocardial infarction; STEMI: ST-segment elevated myocardial infarction; NSTEMI: Non-ST-segment elevated myocardial infarction.

> post-COVID-19-vaccinated patient in April 2022, and the patient also had a history of myocarditis. A possible explanation was the transient atrial fibrillation or plaque rupture after the myocarditis[42]. Therefore, myocarditis on the one hand is a primary complication of COVID-19 vaccination and on the other hand is a secondary cause of MI development after COVID-19 vaccination.



Figure 4 Frequency of studies reporting myocardial infarction after coronavirus disease 2019 vaccination in different countries.

In his blog, Labos wrote a critique in which he pointed out that in order to state the link between inflammation and MI after COVID-19 vaccination, the inflammatory biomarkers need to be measured before, soon after, and a month after vaccination[43]. Jabagi et al[10] proved that there was no association between increased risk of MI post Pfizer vaccination for COVID-19. He did a serial analysis 1 d, 1 wk, and 2 wk post vaccination[10].

Kounis syndrome is one of the mechanisms identified for the occurrence of MI post COVID-19 vaccination as it has been observed in various patients who received a COVID-19 vaccination (Pfizer, AstraZeneca, and Sinovac vaccines)[5,15]. It manifests as an acute coronary syndrome accompanied by mast cell activation due to hypersensitivity or an allergic or anaphylactic reaction[44]. It is more commonly linked with STEMI, which probably explains the higher percentage of STEMI cases after COVID-19 vaccination compared to NSTEMI in the present research.

Vaccine-induced thrombotic thrombocytopenia is another mechanism linking MI with COVID-19 vaccines. In vaccine-induced thrombotic thrombocytopenia, tetramers of platelet factor 4 crosslink with vaccine proteins to form multimolecular aggregates. The ethylenediamine tetraacetic acid in the vaccine possibly causes capillary leakage and dissemination of components in the blood. The multimolecular aggregates are recognized by immunoglobulin G antibodies, which activate platelets, neutrophils, and the complement system, resulting in massive coagulation system activation<sup>[45]</sup>. This can lead to MI and eventually mortality or long-term morbidity.

Polysorbate 80, an excipient in the AstraZeneca vaccine, is seen to trigger allergic reactions in those allergic to the compound. Similarly, polyethylene glycol is the excipient found in Pfizer and is a cause of severe anaphylaxis in those allergic to polyethylene glycol. However, polyethylene glycol allergy is very rare compared to polysorbate 80 allergy [46], which probably explains the increased number of MI cases reported in patients vaccinated with AstraZeneca compared to other vaccines.

The literature searched and analyzed in this study was quite diverse. Therefore, one of the challenges faced while compiling this review was to bring the results under one umbrella. It was observed that robust original research needs to be conducted to probe the mechanisms of and the association between MI and COVID-19 vaccination. Considering the amount of clinical evidence available linking MI with COVID-19 vaccination, it is a bit early to make definitive deductions regarding their link.

#### CONCLUSION

It can be concluded that there is a link between COVID-19 vaccinations and MI in temporal terms of occurrence. However, there is also a possibility that the link was found purely by chance as a majority of cases were reported within 1 d, which is too short a time for a build-up of definitive causative mechanisms for MI. This is due to the diversity of risk factors for MI, such as age, gender, body mass index, ethnicity, and physical/mental stressors. This link can be definitively proven by conducting research while considering the confounders. AstraZeneca was seen to induce the greatest amount of



coronary artery disease, with STEMI as the leading type, and this primarily followed the first vaccination dose.

### **ARTICLE HIGHLIGHTS**

#### Research background

Coronavirus disease 2019 (COVID-19) was first identified November 2019 and subsequently caused a world pandemic. The development of vaccines was quickly achieved with the first vaccinations occurring in December 2020. From then on, a global campaign commenced to vaccinate the majority of the world's population. The implications of these vaccines have been researched abundantly.

#### **Research motivation**

The side effects of COVID-19 vaccines, particularly serious cardiovascular side effects, mention myocarditis. However, myocardial infarction (MI) and its link with COVID-19 vaccines remain unclear.

#### **Research objectives**

To investigate and pinpoint if any link exists between COVID-19 vaccination and MI amongst the vaccinated individuals.

#### **Research methods**

We devised a search strategy to search MEDLINE, EMBASE, and PakMediNet. All studies that reported MI after COVID-19 vaccine delivery were included in this research. A structured data extraction form was developed to extract the data from the eligible studies.

#### **Research results**

The majority of MI cases reported were after vaccination with the AstraZeneca vaccine. Out of all the studies, 69% reported MI cases after the first COVID-19 vaccination dose and 14% after the second. The majority (44%) of MI reported was STEMI.

#### **Research conclusions**

Many studies linked MI to COVID-19 vaccinations, but no definitive association could be found.

#### Research perspectives

More robust clinical trials in this regard could clarify the link between COVID-19 vaccinations and MI.

### FOOTNOTES

**Author contributions:** Zafar U and Zafar H designed the research and analyzed the data and checked paper for final review; Ahmed MS and Khattak M performed the research and wrote the paper.

**Conflict-of-interest statement:** All the authors report no relevant conflicts of interest for this article.

**PRISMA 2009 Checklist statement:** The authors have read the PRISMA 2009 Checklist, and the manuscript was prepared and revised in accordance with this checklist.

**Open-Access:** This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/

Country/Territory of origin: Pakistan

**ORCID number:** Umema Zafar 0000-0002-0450-6602.

S-Editor: Gong ZM L-Editor: Filipodia P-Editor: Gong ZM

Zaisbideng® WJCC | https://www.wjgnet.com

#### REFERENCES

- 1 Sultana J, Mazzaglia G, Luxi N, Cancellieri A, Capuano A, Ferrajolo C, de Waure C, Ferlazzo G, Trifirò G. Potential effects of vaccinations on the prevention of COVID-19: rationale, clinical evidence, risks, and public health considerations. Expert Rev Vaccines 2020; 19: 919-936 [PMID: 32940090 DOI: 10.1080/14760584.2020.1825951]
- 2 Yuan P, Ai P, Liu Y, Ai Z, Wang Y, Cao W, Xia X, Zheng JC. Safety, Tolerability, and Immunogenicity of COVID-19 Vaccines: A Systematic Review and Meta-Analysis. medRxiv 2020 [PMID: 33173896 DOI: 10.1101/2020.11.03.20224998]
- Majumder J, Minko T. Recent Developments on Therapeutic and Diagnostic Approaches for COVID-19. AAPS J 2021; 23: 14 [PMID: 33400058 DOI: 10.1208/s12248-020-00532-2]
- 4 Umakanthan S, Sahu P, Ranade AV, Bukelo MM, Rao JS, Abrahao-Machado LF, Dahal S, Kumar H, Kv D. Origin, transmission, diagnosis and management of coronavirus disease 2019 (COVID-19). Postgrad Med J 2020; 96: 753-758 [PMID: 32563999 DOI: 10.1136/postgradmedj-2020-138234]
- Shiravi AA, Ardekani A, Sheikhbahaei E, Heshmat-Ghahdarijani K. Cardiovascular Complications of SARS-CoV-2 5 Vaccines: An Overview. Cardiol Ther 2022; 11: 13-21 [PMID: 34845662 DOI: 10.1007/s40119-021-00248-0]
- Barsha SY, Akiful Haque MM, Rashid MU, Rahman ML, Hossain MA, Zaman S, Bhuiyan E, Sultana R, Hossian M, Nabi 6 MH, Hawlader MDH. A case of acute encephalopathy and non-ST segment elevation myocardial infarction following mRNA-1273 vaccination: possible adverse effect? Clin Exp Vaccine Res 2021; 10: 293-297 [PMID: 34703815 DOI: 10.7774/cevr.2021.10.3.293
- Hana D, Patel K, Roman S, Gattas B, Sofka S. Clinical Cardiovascular Adverse Events Reported Post-COVID-19 7 Vaccination: Are They a Real Risk? Curr Probl Cardiol 2022; 47: 101077 [PMID: 34902392 DOI: 10.1016/j.cpcardiol.2021.101077]
- Law MR, Watt HC, Wald NJ. The underlying risk of death after myocardial infarction in the absence of treatment. Arch Intern Med 2002; 162: 2405-2410 [PMID: 12437397 DOI: 10.1001/archinte.162.21.2405]
- Johansson S, Rosengren A, Young K, Jennings E. Mortality and morbidity trends after the first year in survivors of acute myocardial infarction: a systematic review. BMC Cardiovasc Disord 2017; 17: 53 [PMID: 28173750 DOI: 10.1186/s12872-017-0482-91
- 10 Jabagi MJ, Botton J, Bertrand M, Weill A, Farrington P, Zureik M, Dray-Spira R. Myocardial Infarction, Stroke, and Pulmonary Embolism After BNT162b2 mRNA COVID-19 Vaccine in People Aged 75 Years or Older. JAMA 2022; 327: 80-82 [PMID: 34807248 DOI: 10.1001/jama.2021.21699]
- 11 Li X, Ostropolets A, Makadia R, Shaoibi A, Rao G, Sena AG, Martinez-Hernandez E, Delmestri A, Verhamme K, Rijnbeek PR, Duarte-Salles T, Suchard M, Ryan P, Hripcsak G, Prieto-Alhambra D. Characterizing the incidence of adverse events of special interest for COVID-19 vaccines across eight countries: a multinational network cohort study. medRxiv 2021 [PMID: 33791732 DOI: 10.1101/2021.03.25.21254315]
- Aye YN, Mai AS, Zhang A, Lim OZH, Lin N, Ng CH, Chan MY, Yip J, Loh PH, Chew NWS. Acute Myocardial Infarction 12 and Myocarditis following COVID-19 Vaccination. QJM 2021 [PMID: 34586408 DOI: 10.1093/qjmed/hcab252]
- 13 Maadarani O, Bitar Z, Elzoueiry M, Nader M, Abdelfatah M, Zaalouk T, Mohsen M, Elhabibi M. Myocardial infarction post COVID-19 vaccine - coincidence, Kounis syndrome or other explanation - time will tell. JRSM Open 2021; 12: 20542704211025259 [PMID: 34394944 DOI: 10.1177/20542704211025259]
- Fazlollahi A, Zahmatyar M, Noori M, Nejadghaderi SA, Sullman MJM, Shekarriz-Foumani R, Kolahi AA, Singh K, Safiri 14 S. Cardiac complications following mRNA COVID-19 vaccines: A systematic review of case reports and case series. Rev Med Virol 2022; 32: e2318 [PMID: 34921468 DOI: 10.1002/rmv.2318]
- Sanci E, Örçen C, Çelik OM, Özen MT, Bozyel S. Kounis syndrome associated with BNT162b2 mRNA COVID-19 15 vaccine presenting as ST-elevation acute myocardial infarction. Anatol J Cardiol 2022; 26: 69-74 [PMID: 35191390 DOI: 10.5152/AnatolJCardiol.2021.1212
- Chatterjee S, Ojha UK, Vardhan B, Tiwari A. Myocardial infarction after COVID-19 vaccination-casual or causal? Diabetes Metab Syndr 2021; 15: 1055-1056 [PMID: 33888439 DOI: 10.1016/j.dsx.2021.04.006]
- Jeet Kaur R, Dutta S, Charan J, Bhardwaj P, Tandon A, Yadav D, Islam S, Haque M. Cardiovascular Adverse Events Reported from COVID-19 Vaccines: A Study Based on WHO Database. Int J Gen Med 2021; 14: 3909-3927 [PMID: 34349544 DOI: 10.2147/IJGM.S324349]
- 18 Iqbal S, Adnan G, Farhad A, Ahmed I, Rahman MN. Acute Myocardial Infarction After Coronavirus Vaccine: A Rare Adverse Effect. Cureus 2022; 14: e21544 [PMID: 35223317 DOI: 10.7759/cureus.21544]
- 19 Cari L, Alhosseini MN, Fiore P, Pierno S, Pacor S, Bergamo A, Sava G, Nocentini G. Cardiovascular, neurological, and pulmonary events following vaccination with the BNT162b2, ChAdOx1 nCoV-19, and Ad26.COV2.S vaccines: An analysis of European data. J Autoimmun 2021; 125: 102742 [PMID: 34710832 DOI: 10.1016/j.jaut.2021.102742]
- 20 Tajstra M, Jaroszewicz J, Gąsior M. Acute Coronary Tree Thrombosis After Vaccination for COVID-19. JACC Cardiovasc Interv 2021; 14: e103-e104 [PMID: 33958175 DOI: 10.1016/j.jcin.2021.03.003]
- Flower L, Bares Z, Santiapillai G, Harris S. Acute ST-segment elevation myocardial infarction secondary to vaccine-21 induced immune thrombosis with thrombocytopaenia (VITT). BMJ Case Rep 2021; 14 [PMID: 34580132 DOI: 10.1136/bcr-2021-245218
- Chiang CY, Chen CY, Yu WL, Kan WC, Feng YH. Myocardial Infarction and Azygos Vein Thrombosis After ChAdOx1 22 nCoV-19 Vaccination in a Hemodialysis Patient. Cureus 2021; 13: e18390 [PMID: 34650896 DOI: 10.7759/cureus.18390]
- Fialho I, Mateus C, Martins-Dos-Santos G, Pita J, Cabanelas N, Baptista SB, Roque D. Recurrent Kounis syndrome a 23 life-threatening event after COVID-19 vaccine administration. J Cardiol Cases 2022; 25: 400-403 [PMID: 35154518 DOI: 10.1016/j.jccase.2022.01.014]
- Hsu MH, Lee CP, Huang YC. Acute ST-Segment Elevation Myocardial Infarction After ChAdOx1 nCoV-19 Vaccination 24 in a 33-Year-Old Man. Ann Emerg Med 2022; 79: 220-221 [PMID: 35065747 DOI: 10.1016/j.annemergmed.2021.12.002]
- Showkathali R, Yalamanchi R, Narra L, Vinayagamoorthy N, Gunasekaran S, Nayak R, Vijayachandra Reddy Y, 25 Mahilmaran A, Srinivasan KN, Oomman A, Kaliyamoorthy D. Coronary thrombo-embolic events after Covid-19 vaccination- a single centre study. Indian Heart J 2022; 74: 131-134 [PMID: 35122777 DOI: 10.1016/j.ihj.2022.01.002]



- 26 Whiteley WN, Ip S, Cooper JA, Bolton T, Keene S, Walker V, Denholm R, Akbari A, Omigie E, Hollings S, Di Angelantonio E, Denaxas S, Wood A, Sterne JAC, Sudlow C; CVD-COVID-UK consortium. Association of COVID-19 vaccines ChAdOx1 and BNT162b2 with major venous, arterial, or thrombocytopenic events: A population-based cohort study of 46 million adults in England. PLoS Med 2022; 19: e1003926 [PMID: 35192597 DOI: 10.1371/journal.pmed.1003926]
- 27 Barda N, Dagan N, Ben-Shlomo Y, Kepten E, Waxman J, Ohana R, Hernán MA, Lipsitch M, Kohane I, Netzer D, Reis BY, Balicer RD. Safety of the BNT162b2 mRNA Covid-19 Vaccine in a Nationwide Setting. N Engl J Med 2021; 385: 1078-1090 [PMID: 34432976 DOI: 10.1056/NEJMoa2110475]
- 28 Boivin Z, Martin J. Untimely Myocardial Infarction or COVID-19 Vaccine Side Effect. Cureus 2021; 13: e13651 [PMID: 33824804 DOI: 10.7759/cureus.13651]
- 29 Hippisley-Cox J, Patone M, Mei XW, Saatci D, Dixon S, Khunti K, Zaccardi F, Watkinson P, Shankar-Hari M, Doidge J, Harrison DA, Griffin SJ, Sheikh A, Coupland CAC. Risk of thrombocytopenia and thromboembolism after covid-19 vaccination and SARS-CoV-2 positive testing: self-controlled case series study. BMJ 2021; 374: n1931 [PMID: 34446426 DOI: 10.1136/bmj.n1931]
- Edler C, Klein A, Schröder AS, Sperhake JP, Ondruschka B. Deaths associated with newly launched SARS-CoV-2 vaccination (Comirnaty®). Leg Med (Tokyo) 2021; 51: 101895 [PMID: 33895650 DOI: 10.1016/j.legalmed.2021.101895]
- 31 Ho JS, Sia CH, Ngiam JN, Loh PH, Chew NW, Kong WK, Poh KK. A review of COVID-19 vaccination and the reported cardiac manifestations. Singapore Med J 2021 [PMID: 34808708 DOI: 10.11622/smedj.2021210]
- Sung JG, Sobieszczyk PS, Bhatt DL. Acute Myocardial Infarction Within 24 Hours After COVID-19 Vaccination. Am J 32 Cardiol 2021; 156: 129-131 [PMID: 34364657 DOI: 10.1016/j.amjcard.2021.06.047]
- Pottegård A, Lund LC, Karlstad Ø, Dahl J, Andersen M, Hallas J, Lidegaard Ø, Tapia G, Gulseth HL, Ruiz PL, Watle SV, 33 Mikkelsen AP, Pedersen L, Sørensen HT, Thomsen RW, Hviid A. Arterial events, venous thromboembolism, thrombocytopenia, and bleeding after vaccination with Oxford-AstraZeneca ChAdOx1-S in Denmark and Norway: population based cohort study. BMJ 2021; 373: n1114 [PMID: 33952445 DOI: 10.1136/bmj.n1114]
- 34 D'Agostino V, Caranci F, Negro A, Piscitelli V, Tuccillo B, Fasano F, Sirabella G, Marano I, Granata V, Grassi R, Pupo D. A Rare Case of Cerebral Venous Thrombosis and Disseminated Intravascular Coagulation Temporally Associated to the COVID-19 Vaccine Administration. J Pers Med 2021; 11 [PMID: 33917902 DOI: 10.3390/jpm11040285]
- 35 Bardenheier BH, Gravenstein S, Blackman C, Gutman R, Sarkar IN, Feifer RA, White EM, McConeghy K, Nanda A, Mor V. Adverse events following mRNA SARS-CoV-2 vaccination among U.S. nursing home residents. Vaccine 2021; 39: 3844-3851 [PMID: 34092431 DOI: 10.1016/j.vaccine.2021.05.088]
- Our World in Data. Coronavirus (COVID-19) Vaccinations. 2022. Available from: https://ourworldindata.org/covid-36 vaccinations#which-vaccines-have-been-administered-in-each-country
- Pakistan: the latest coronavirus counts, charts and maps [Internet]. Reuters. 2022 Available from: 37 https://graphics.reuters.com/world-coronavirus-tracker-and-maps/countries-and-territories/pakistan/
- UW-Madison. What is the difference between an additional dose and a booster shot ? COVID-19 Response. 2022. 38 Available from: https://covidresponse.wisc.edu/faq/what-is-the-difference-between-a-third-dose-and-a-booster-shot/
- 39 Leigh S. COVID-19 Vaccines Produce Immune Responses in Patients With Chronic Inflammatory Diseases COVID-19 Vaccine 'Clearly a Benefit' Despite. 2021. Available from: https://www.ucsf.edu/news/2021/08/421346/covid-19-vaccinesproduce-immune-responses-patients-chronic-inflammatory
- Hervé C, Laupèze B, Del Giudice G, Didierlaurent AM, Tavares Da Silva F. The how's and what's of vaccine 40 reactogenicity. NPJ Vaccines 2019; 4: 39 [PMID: 31583123 DOI: 10.1038/s41541-019-0132-6]
- 41 McManus DD, Gore J, Yarzebski J, Spencer F, Lessard D, Goldberg RJ. Recent trends in the incidence, treatment, and outcomes of patients with STEMI and NSTEMI. Am J Med 2011; 124: 40-47 [PMID: 21187184 DOI: 10.1016/j.amjmed.2010.07.023]
- Botros MB, Narvaez-Guerra O, Aurigemma GP, Harrington C. STEMI following MRNA COVID-19 vaccination. J Am 42 Coll Cardiol 2022; 79 (9 Suppl): 2341 [DOI: 10.1016/s0735-1097(22)0332-0]
- Labos C. Do the COVID-19 Vaccines Really Increase MI What to Read Next on Medscape. Medscape 2022. Available from: https://www.medscape.com/viewarticle/964358
- Memon S, Chhabra L, Masrur S, Parker MW. Allergic acute coronary syndrome (Kounis syndrome). Proc (Bayl Univ Med 44 Cent) 2015; 28: 358-362 [PMID: 26130889 DOI: 10.1080/08998280.2015.11929274]
- 45 John CV, Kumar R, Sivan AK, Jithin S, Abraham R, Philip CC. Vaccine-induced thrombotic thrombocytopenia (VITT): first report from India. Thromb J 2022; 20: 11 [PMID: 35246163 DOI: 10.1186/s12959-022-00370-6]
- Sellaturay P, Gurugama P, Harper V, Dymond T, Ewan P, Nasser S. The Polysorbate containing AstraZeneca COVID-19 46 vaccine is tolerated by polyethylene glycol (PEG) allergic patients. Clin Exp Allergy 2022; 52: 12-17 [PMID: 34822190 DOI: 10.1111/cea.14064]





## Published by Baishideng Publishing Group Inc 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA Telephone: +1-925-3991568 E-mail: bpgoffice@wjgnet.com Help Desk: https://www.f6publishing.com/helpdesk https://www.wjgnet.com

